[Federal Register Volume 75, Number 134 (Wednesday, July 14, 2010)]
[Notices]
[Pages 40795-40796]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2010-17173]


-----------------------------------------------------------------------

DEPARTMENT OF COMMERCE

Foreign-Trade Zones Board

[Docket 44-2010]


Review of Sourcing Change, Foreign-Trade Subzone 61H, Baxter 
Healthcare of Puerto Rico (Inhalation Anesthetics Manufacturing), 
Guayama, Puerto Rico

    Pursuant to the regulations of the Foreign-Trade Zones (FTZ) Board 
(the Board), a review has been initiated (under 15 CFR Sec. 
400.28(a)(3)(iii)(A)) of changes in sourcing related to inhalation 
anesthetics at Foreign-Trade Subzone 61H, at the facility of Baxter 
Healthcare of Puerto Rico (Baxter).
    Subzone 61H was approved by the FTZ Board on February 25, 1997 
(Board Order 875, 62 FR 10521, 3/7/1997) at the Baxter Healthcare of 
Puerto Rico (Baxter) (formerly Ohmeda Caribe Inc./Ohmeda Pharmaceutical 
Manufacturing Inc.) facility in Guayama, Puerto Rico, for the 
manufacturing and distribution of pharmaceutical products, primarily 
inhalation anesthetics for hospital and critical care therapy. The 
subzone was initially approved for a period of five years. On August 
25, 2003 (Board Order 1293, 68 FR 53346, 9/10/2003), the subzone was 
extended indefinitely and the scope of approved authority was expanded.
    On products shipped to the U.S. market, the company is able to 
choose the duty rate during customs entry procedures that applies to 
the finished products (duty-free) for the otherwise dutiable foreign 
components (duty rates range from duty-free to 20%).
    Baxter has now notified the Board of additional sourcing of two 
chemical inputs. The new foreign-sourced chemical ingredients are 
sevomethylether (HTSUS 2909.19.1800 5.5%) and N,N-diisopropylethylamine 
(HTSUS 2921.19.6090 - 6.5%). The use of zone procedures for the 
additional inputs could exempt Baxter from customs duty payments on the 
foreign components used in export production. The company estimates 
that some 40 percent of the plant's shipments are exported. On the 
domestic sales, Baxter would be able to choose the duty rate during 
customs entry procedures that applies to the finished inhalation 
anesthetics (duty-free) for the foreign inputs noted above. The 
finished products remain unchanged and were included in the scope of 
manufacturing authority approved by the Board.
    In accordance with the Board's regulations, Diane Finver of the FTZ 
Staff is designated examiner to investigate the sourcing change, 
including its potential to cause ``significant adverse effects'' (15 
CFR 400.28(a)(3)(iii)(A)), and report to the Board. Public comment is 
invited from interested parties. Submissions (original and 3 copies) 
shall be addressed to the Board's Executive Secretary at the address 
below. The closing period for their receipt is August 13, 2010. 
Rebuttal comments in response to material submitted during the 
foregoing period may be submitted during the subsequent 15-day period 
to August 30, 2010.
    A copy of the application will be available for public inspection 
at the Office of the Executive Secretary, Foreign-Trade Zones Board, 
Room 2111, U.S. Department of Commerce, 1401 Constitution Avenue, NW, 
Washington, DC 20230-0002, and in the

[[Page 40796]]

``Reading Room'' section of the Board's website, which is accessible 
via www.trade.gov/ftz.
    For further information, contact Diane Finver at 
[email protected] or 482-1367.

    Dated: July 2, 2010.
Andrew McGilvray,
Executive Secretary.
[FR Doc. 2010-17173 Filed 7-13-10; 8:45 am]
BILLING CODE 3510-DS-S